Zenotech swings to ₹45.55 lakh net loss in Q1 on higher costs
Revenue from operations rises 11% but employee and other expenses push the nano-cap pharma company into the red, versus a profit of ₹98.96 lakh a year ago.
— 1 earlier story on Zenotech Laboratories Ltd. →What's new
- Net loss of ₹45.55 lakh for Q1 June 2026 against a ₹98.96 lakh profit a year ago.
- Revenue from operations up 11% to ₹959.64 lakh.
- Employee and other expenses pushed the company into the red.
Why this matters
For a ₹279-cr market-cap pharma with zero debt, the swing to loss is a meaningful deviation even if quarterly results are routine filings. Revenue growth couldn't offset cost pressures, raising questions about margin trajectory, particularly given the company's trailing PAT decline of 356.3%.
What we're watching
- Whether cost control measures emerge in the next quarter's disclosure.
- Any change in revenue composition or one-off expense items.
- Management commentary during the AGM on the earnings outlook.
The full read
Zenotech Laboratories reported a net loss of ₹45.55 lakh for the June quarter, swinging from a profit of ₹98.96 lakh a year earlier. Revenue rose 11% to ₹959.64 lakh, but employee and other expenses ate into margins. For a ₹279-cr market-cap pharma with zero debt and a trailing ROE of 5.8%, the loss stands out, especially as trailing revenue is down 18.6% and PAT has slumped 356.3%. The AGM scheduling for September is routine. One quarter doesn't make a trend, but for a company that was profitable a year ago, this is a step back. Whether cost pressures ease in coming quarters will determine if this is a blip or a shift.
Questions answered
- What caused the net loss in Q1 FY27?
- Employee and other expenses climbed, more than offsetting an 11% revenue rise to ₹959.64 lakh. The company had posted a profit of ₹98.96 lakh in the same quarter last year.
- How does this compare to the company's trailing performance?
- On a trailing basis (screener data, period may differ), revenue is down 18.6% and profit after tax is down 356.3%: the Q1 loss extends a deteriorating trend.
- What is Zenotech's balance sheet strength?
- The company has zero debt and a return on equity of 5.8%, which provides some cushion despite the quarterly loss.
- Was the AGM schedule material news?
- No, the 37th AGM set for September 25, 2026 via videoconference is a routine procedural announcement with no new strategic information.
- How should investors interpret a single quarter's loss for a nano-cap?
- Nano-cap earnings can be volatile quarter-to-quarter. The loss is notable but does not alone signal a structural downturn unless repeated.
Story so far
All notes on ZENOTECH →- 28 Jul 2026 · 2:49 PM IST Zenotech swings to ₹45.55 lakh net loss in Q1 on higher costs
- today Zenotech posts ₹45.55 lakh net loss in Q1 as costs surge